Kolon Life Science Inc (102940) — Cash Flow-to-Debt Ratio
Kolon Life Science Inc (102940) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of ₩2.58 Billion could theoretically repay 0% of its total liabilities (₩295.72 Billion) in one year. See 102940 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kolon Life Science Inc Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Kolon Life Science Inc across 11 annual periods. Also explore Kolon Life Science Inc equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Kolon Life Science Inc (2014–2024)
Year-by-year debt coverage analysis for Kolon Life Science Inc. For market capitalisation and broader financial context, see Kolon Life Science Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.05x | ₩-14.08 Billion | ₩270.23 Billion | ▲ +64.0% |
| 2023 | -0.14x | ₩-24.87 Billion | ₩171.76 Billion | ▼ -1.6% |
| 2022 | -0.14x | ₩-20.85 Billion | ₩146.39 Billion | ▼ -19.0% |
| 2021 | -0.12x | ₩-16.19 Billion | ₩135.25 Billion | ▼ -211.8% |
| 2020 | -0.04x | ₩-7.31 Billion | ₩190.38 Billion | ▲ +66.3% |
| 2019 | -0.11x | ₩-20.18 Billion | ₩177.27 Billion | ▼ -44.6% |
| 2018 | -0.08x | ₩-13.60 Billion | ₩172.76 Billion | ▼ -62.7% |
| 2017 | -0.05x | ₩-8.29 Billion | ₩171.38 Billion | ▼ -116.3% |
| 2016 | 0.30x | ₩28.11 Billion | ₩94.78 Billion | ▲ +32.8% |
| 2015 | 0.22x | ₩20.81 Billion | ₩93.17 Billion | ▲ +34.3% |
| 2014 | 0.17x | ₩12.10 Billion | ₩72.72 Billion | — |